At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Tacrolimus +3 moredrug
Likely dose
Prednisone 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients
In Brief
A clinical study evaluating Tacrolimus, Prednisone, and 2 other interventions for Immunosuppression. Completed, enrolled 40 participants across 1 site.
Detailed Summary
With the availability of well-studied once-daily formulations of tacrolimus, the ability to achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may finally be achievable and have the potential to optimize immunosuppression safety and efficacy in kidney transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionDec 2018
TodayJul 2026
First PostedNov 3, 2016
Enrollment StartDec 1, 2016
Primary CompletionDec 27, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.7 years ago
Interventions
Tacrolimusdrug
goal trough level 5-12ng/mL
Prednisonedrug
goal dose 5mg QD
Mycophenolate mofetildrug
goal dose 1g BID
Everolimusdrug
goal trough level 3-8ng/mL